OBJECTIVES: New treatments for Hepatitis C offer higher rates of cure with fewer side effects, yet therapy costs are high. While new direct-acting antiviral agents (DAAs) have become the standard of care, providers and payers feel pressured to prioritize treatment due to high drug costs. We aim to examine the association of patient demographic, clinical and provider characteristics associated with DAAs. treatment. METHODS:  Using electronic health record data from Kaiser Permanente Mid-Atlantic States (KPMAS), we constructed a Cox hazards model to examine the association between different patient factors on the “risk” of treatment over the study period. Our study sample included 3,017 patients with a confirmed diagnosis of Hepatitis C from the KPMAS Hepatitis C registry, as per pre-specified clinical criteria. The study period began on November 1, 2013 with the release of the initial second generation DAAs and concluded on May 31, 2016. RESULTS: In a Hepatitis C panel of 3017, 995 patients (33%) initiated DAA therapy over the course of the study period. Most patients were between the ages of 61-80 (55%), Black (67%) and male (62%). About 24% of patients were censored due to death or disenrollment from the health plan prior to the end of follow-up. Log-rank tests at baseline showed differences in probability of treatment by age category, prior treatment experience and race category. A multivariable cox hazards model showed older age, between 40-80 years, so be significantly associated with increased probability of treatment. Differences in fibrosis scores did not significantly change the likelihood of treatment in our sample. CONCLUSIONS: While our analysis shows that age impacts time-to-treatment with a DAAs, we need to better understand the reasons for this patterns in treatment. Further research with a longer follow-up period that covers the more recently approved pan-genotypic DAAs may provide more insight into treatment decisions.